Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs."
Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda.
The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among... [2678 chars]